BLACKLEDGER Buying Watch: ABOS, MU, ANET
BLACKLEDGER's latest buying watch update tracks ABOS, MU, ANET, VKTX, AMD, TSM from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.
Buying Watch Data
The dedicated feed category for this update is Buying. The latest public scan timestamp is 2026-06-23T08:00:46.255134+00:00.
- ABOS (stock): Bull public bias, Extended, public score 9.0/10, status: Paper trading research.
- MU (stock): Bull public bias, Extended, public score 8.0/10, status: Paper trading research.
- ANET (stock): Bull public bias, Extended, public score 8.0/10, status: Paper trading research.
- VKTX (stock): Bull public bias, Extended, public score 8.0/10, status: Paper trading research.
- AMD (stock): Bull public bias, Extended, public score 8.0/10, status: Paper trading research.
- TSM (stock): Bull public bias, Extended, public score 8.0/10, status: Paper trading research.
- USD/CAD (forex): Bull public bias, A-List, public score 5.8/10, status: Paper trading research.
- USD/MXN (forex): Bull public bias, A-List, public score 5.8/10, status: Paper trading research.
Educational Context: How To Use This Page
This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.
ABOS Public Research Bio
Name: Acumen Pharmaceuticals, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Latest public price/reference: $2.385
- Public market capitalization: $173.35M
- Recent public volume/reference: 571.69K
- One-month public movement: 8.66%
- Sector/category: Healthcare
Why ABOS Is In This Public Update
- BLACKLEDGER public score is in the upgrade-candidate band, so the asset receives expanded public context.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease — Exec Edge
- Acumen Pharmaceuticals Inc (ABOS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... — GuruFocus.com
- Acumen Pharmaceuticals Q1 Earnings Call Highlights — MarketBeat
- Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Zacks
MU Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Micron Technology, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Micron Technology, Inc. designs, develops, manufactures, and sells memory and storage products in the United States, Taiwan, Japan, Mainland China, Hong Kong, Europe, and internationally. It operates through the Cloud Memory Business Unit; Core Data Center Business Unit; Mobile and Client Business Unit; and Automotive and Embedded Business Unit segments. The company provides memory products, including dynamic random access memory components and modules, CXL-based memory, LPDDR components and modules, graphics memory, high-bandwidth memory, and data center memory products; multichip packages (MCP) comprising embedded multimedia card-based, universal flash storage-based, and NAND-based MCPs; and technology leadership products that include 1y DRAM and G9 NAND technologies. It also offers storage products, such as data center solid-state drives (SSD), client SSD storage, and auto and industrial SSD storage; managed NAND; NAND flash; NOR fla
- Latest public price/reference: $1.21K
- Public market capitalization: $1366.11B
- Recent public volume/reference: 47.96M
- One-month public movement: 29.15%
- Sector/category: Technology
Why MU Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Stock market today: Dow, S&P 500, Nasdaq futures plunge as Wall Street weighs US-Iran talks, AI trade — Yahoo Finance
- Micron stock hits an all-time high, thanks to the new Anthropic deal — Yahoo Finance Video
- SK Hynix soars to new heights, becomes South Korea's most valuable company — Yahoo Finance Video
- Cerebras Just Had Its IPO. Now, the Chip Maker Faces Its Next Big Test. — Barrons.com
ANET Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Arista Networks, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Arista Networks, Inc. engages in the development, marketing, and sale of data-driven, client to cloud networking solutions for AI, data center, campus, and routing environments in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. Its cloud networking solutions consist of Extensible Operating System (EOS), a publish-subscribe state-sharing networking operating system offered in combination with a set of network applications. The company offers data center, cloud and AI networking, cognitive adjacencies, and cognitive network software and services. It also provides post contract customer support services, such as technical support, hardware repair and replacement parts beyond standard warranty, bug fixes, patches, and upgrade services. The company serves a range of industries comprising internet companies, cloud service providers, financial services organizations, government agencies, media and entertainment, healthcare
- Latest public price/reference: $174.6
- Public market capitalization: $219.80B
- Recent public volume/reference: 7.82M
- One-month public movement: 11.25%
- Sector/category: Technology
Why ANET Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Cisco Stock Looks Strong, But One Number Says Be Careful — Trefis
- Exclusive: Upscale AI wants to be the next Cisco—and it just raised another $190 million — Fortune
- Cisco is Overvalued at 7.01X P/S: Should You Still Buy the Stock? — Zacks
- Wolfe Research Reaffirms Bullish View on Arista Networks (ANET) With $175 Price Target — Insider Monkey
VKTX Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Viking Therapeutics, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystr
- Latest public price/reference: $32.36
- Public market capitalization: $3.76B
- Recent public volume/reference: 3.25M
- One-month public movement: 12.77%
- Sector/category: Healthcare
Why VKTX Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Is Viking Therapeutics Stock a No-Brainer Buy Below $35? — Motley Fool
- Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk — Motley Fool
- Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 Years — Motley Fool
- Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know — Zacks
AMD Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Advanced Micro Devices, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.
Advanced Micro Devices, Inc. operates as a semiconductor company internationally. It operates in three segments: Data Center, Client and Gaming, and Embedded. The company offers artificial intelligence (AI) accelerators, microprocessors, and graphics processing units (GPUs) as standalone devices or as incorporated into accelerated processing units, chipsets, and data center and professional GPUs; and embedded processors and semi-custom system-on-chip (SoC) products, microprocessor and SoC development services and technology, data processing units, field programmable gate arrays (FPGA), system on modules, AI network interface cards, and adaptive SoC products. It provides processors under the AMD Ryzen, AMD Ryzen AI, AMD Ryzen PRO, AMD Ryzen Threadripper, AMD Ryzen Threadripper PRO, AMD Athlon, and AMD PRO A-Series brands; graphics under the AMD Radeon graphics and AMD Embedded Radeon graphics; professional graphics under the AMD Radeon P
- Latest public price/reference: $551.7
- Public market capitalization: $899.49B
- Recent public volume/reference: 25.25M
- One-month public movement: 13.27%
- Sector/category: Technology
Why AMD Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- Nasdaq, S&P 500 Futures Dip After Megacap Tech Selloff: Why SPCX, INFQ, PLTR, QBTS, HIMS Are In Focus — Stocktwits
- NVIDIA Stock's Next Big Move Might Not Involve A GPU — Trefis
- Dell’s AI-Focused Spending Spree and New Debt Financing Could Be A Game Changer For Dell Technologies (DELL) — Simply Wall St.
- Advanced Micro Devices (AMD) Ascends While Market Falls: Some Facts to Note — Zacks
TSM Public Research Bio
Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.
Name: Taiwan Semiconductor Manufacturing Company Limited. Market class: stock. Public bias: Bull. Public tier: Extended.
Taiwan Semiconductor Manufacturing Company Limited, together with its subsidiaries, manufactures, packages, tests, and sells integrated circuits and other semiconductor devices in Taiwan, China, Europe, the Middle East, Africa, Japan, the United States, and internationally. It provides various wafer fabrication processes, such as processes to manufacture complementary metal- oxide-semiconductor (CMOS) logic, mixed-signal, radio frequency, embedded memory, bipolar CMOS mixed-signal, and others. The company also involved in providing customer and engineering support services; manufacturing of masks; investment in technology start-up companies; research, designing, developing, manufacturing, packaging, testing, and sale of color filters; and investment activities. Its products are used in high performance computing, [redacted]rtphones, Internet of things, automotive, and digital consumer electronics. Taiwan Semiconductor Manufacturing Comp
- Latest public price/reference: $467.6
- Public market capitalization: $2425.56B
- Recent public volume/reference: 13.63M
- One-month public movement: 9.18%
- Sector/category: Technology
Why TSM Is In This Public Update
- BLACKLEDGER public score is in the 7.0-8.9 confirmation band (the most reliable tier), so this asset receives a deep public bio and outside-source review.
- Current public status: Paper trading research. Public confidence label: High Confidence.
- Current public directional label: bull. This is research context only, not an execution instruction.
Outside Public Headlines / Source Notes
- ‘FOMO Really Got Me’: Taiwanese Go Deep Into Debt to Amp 100% Stock Rally — Bloomberg
- TSMC (TSM) Advances While Market Declines: Some Information for Investors — Zacks
- Cerebras gets set for inaugural earnings with upside potential, Wedbush says — Proactive
- The Best-Performing Dividend ETFs Have a Big AI Bet — Barrons.com
What The Public Data Shows
The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.
Why This Category Matters
The Buying section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.
Research-Only Notice
BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.
Research-only. No execution signal. Not financial advice.